Objective?By detecting the changes of serum interleukin-5 (IL-5) and tumor necrosis factor -α (TNF-α) before and after treatment, to explore the effect of Sanfu patch in the treatment of patients with chronic obstructive pulmonary disease at stable stage. Methods?A total of 80 patients with stable COPD who were admitted to the Affiliated Hospital of Panzhihua University from June to August 2019 were selected as the research objects, and were divided into a treatment group and a control group according to the random number table method, with 40 cases in each. The patients in the control group maintained the conventional treatment plan, and the patients in the treatment group were additionally treated with Sanfu patch on the basis of the control group. The levels of serum IL-5, TNF-α, chronic obstructive pulmonary disease assessment test (CAT) score, St. George's Respiratory Questionnaire (SGRQ) score, 6-minute walk test (6MWT) and pulmonary function were compared between the two groups before treatment and 3 months after treatment. Results?Serum IL-5 and TNF in the treatment group- α Level, cat score, SGRQ score, 6MWT and pulmonary function were significantly improved compared with those before treatment (P ＜ 0.05); There was no significant difference in the indexes of the control group before and after treatment (P ＞ 0.05). After treatment, the clinical symptoms of the patients in the treatment group were significantly improved, the TCM syndrome score was reduced, and the pulmonary function was improved. Therefore, the TCM syndrome score in the treatment group was lower than that in the control group, the pulmonary function index was better than that in the control group (P ＜0.05); The effective rate of the treatment group was higher than that of the control group (P ＜0.05). Conclusion?Sanfu patch can improve the CAT score, SGRQ, 6MWT and pulmonary function in patients with stable COPD by reducing the levels of serum IL-5 and TNF-α.